Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer

Alfred I. Neugut, Grace Clarke Hillyer, Lawrence H. Kushi, Lois Lamerato, Nicole Leoce, Christine B. Ambrosone, Dana H. Bovbjerg, Jeanne S. Mandelblatt, Dawn L. Hershman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

One year of trastuzumab therapy is recommended for women with HER2-positive breast cancer ≥1.0 cm in size to increase survival and is considered for women with tumors 0.5–0.9 cm in size. We analyzed compliance with trastuzumab among women with HER2-positive breast cancer in a prospective cohort study. Of 1145 recruited patients with breast cancer, 152 were HER2-positive (13.2 %), of whom 126 had tumors ≥1.0 cm; 110/126 (87.3 %) of these initiated trastuzumab. Non-receipt was associated with older age, better prognosis tumors, and with non-receipt of adjuvant chemotherapy. Of the 110 who initiated treatment, 18 (15 %) did not complete treatment, 15 (83 %) of them because of cardiotoxicity. Of 20 women with tumors 0.5–0.9 cm, 5 (25 %) initiated trastuzumab. Compliance with trastuzumab was very high among those with HER2-positive breast cancer, as was the completion of the recommended therapy.

Original languageEnglish (US)
Pages (from-to)780-785
Number of pages6
JournalBreast Cancer
Volume21
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Breast Neoplasms
Neoplasms
Therapeutics
Adjuvant Chemotherapy
Cohort Studies
Trastuzumab
Prospective Studies
Survival

Keywords

  • Adherence
  • Adjuvant therapy
  • Breast cancer
  • Early discontinuation
  • Non-initiation
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Neugut, A. I., Hillyer, G. C., Kushi, L. H., Lamerato, L., Leoce, N., Ambrosone, C. B., ... Hershman, D. L. (2014). Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer. Breast Cancer, 21(6), 780-785. https://doi.org/10.1007/s12282-014-0543-1

Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer. / Neugut, Alfred I.; Hillyer, Grace Clarke; Kushi, Lawrence H.; Lamerato, Lois; Leoce, Nicole; Ambrosone, Christine B.; Bovbjerg, Dana H.; Mandelblatt, Jeanne S.; Hershman, Dawn L.

In: Breast Cancer, Vol. 21, No. 6, 2014, p. 780-785.

Research output: Contribution to journalArticle

Neugut, AI, Hillyer, GC, Kushi, LH, Lamerato, L, Leoce, N, Ambrosone, CB, Bovbjerg, DH, Mandelblatt, JS & Hershman, DL 2014, 'Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer', Breast Cancer, vol. 21, no. 6, pp. 780-785. https://doi.org/10.1007/s12282-014-0543-1
Neugut, Alfred I. ; Hillyer, Grace Clarke ; Kushi, Lawrence H. ; Lamerato, Lois ; Leoce, Nicole ; Ambrosone, Christine B. ; Bovbjerg, Dana H. ; Mandelblatt, Jeanne S. ; Hershman, Dawn L. / Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer. In: Breast Cancer. 2014 ; Vol. 21, No. 6. pp. 780-785.
@article{401531ddc6684129a67a58d4315d45a7,
title = "Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer",
abstract = "One year of trastuzumab therapy is recommended for women with HER2-positive breast cancer ≥1.0 cm in size to increase survival and is considered for women with tumors 0.5–0.9 cm in size. We analyzed compliance with trastuzumab among women with HER2-positive breast cancer in a prospective cohort study. Of 1145 recruited patients with breast cancer, 152 were HER2-positive (13.2 {\%}), of whom 126 had tumors ≥1.0 cm; 110/126 (87.3 {\%}) of these initiated trastuzumab. Non-receipt was associated with older age, better prognosis tumors, and with non-receipt of adjuvant chemotherapy. Of the 110 who initiated treatment, 18 (15 {\%}) did not complete treatment, 15 (83 {\%}) of them because of cardiotoxicity. Of 20 women with tumors 0.5–0.9 cm, 5 (25 {\%}) initiated trastuzumab. Compliance with trastuzumab was very high among those with HER2-positive breast cancer, as was the completion of the recommended therapy.",
keywords = "Adherence, Adjuvant therapy, Breast cancer, Early discontinuation, Non-initiation, Trastuzumab",
author = "Neugut, {Alfred I.} and Hillyer, {Grace Clarke} and Kushi, {Lawrence H.} and Lois Lamerato and Nicole Leoce and Ambrosone, {Christine B.} and Bovbjerg, {Dana H.} and Mandelblatt, {Jeanne S.} and Hershman, {Dawn L.}",
year = "2014",
doi = "10.1007/s12282-014-0543-1",
language = "English (US)",
volume = "21",
pages = "780--785",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer

AU - Neugut, Alfred I.

AU - Hillyer, Grace Clarke

AU - Kushi, Lawrence H.

AU - Lamerato, Lois

AU - Leoce, Nicole

AU - Ambrosone, Christine B.

AU - Bovbjerg, Dana H.

AU - Mandelblatt, Jeanne S.

AU - Hershman, Dawn L.

PY - 2014

Y1 - 2014

N2 - One year of trastuzumab therapy is recommended for women with HER2-positive breast cancer ≥1.0 cm in size to increase survival and is considered for women with tumors 0.5–0.9 cm in size. We analyzed compliance with trastuzumab among women with HER2-positive breast cancer in a prospective cohort study. Of 1145 recruited patients with breast cancer, 152 were HER2-positive (13.2 %), of whom 126 had tumors ≥1.0 cm; 110/126 (87.3 %) of these initiated trastuzumab. Non-receipt was associated with older age, better prognosis tumors, and with non-receipt of adjuvant chemotherapy. Of the 110 who initiated treatment, 18 (15 %) did not complete treatment, 15 (83 %) of them because of cardiotoxicity. Of 20 women with tumors 0.5–0.9 cm, 5 (25 %) initiated trastuzumab. Compliance with trastuzumab was very high among those with HER2-positive breast cancer, as was the completion of the recommended therapy.

AB - One year of trastuzumab therapy is recommended for women with HER2-positive breast cancer ≥1.0 cm in size to increase survival and is considered for women with tumors 0.5–0.9 cm in size. We analyzed compliance with trastuzumab among women with HER2-positive breast cancer in a prospective cohort study. Of 1145 recruited patients with breast cancer, 152 were HER2-positive (13.2 %), of whom 126 had tumors ≥1.0 cm; 110/126 (87.3 %) of these initiated trastuzumab. Non-receipt was associated with older age, better prognosis tumors, and with non-receipt of adjuvant chemotherapy. Of the 110 who initiated treatment, 18 (15 %) did not complete treatment, 15 (83 %) of them because of cardiotoxicity. Of 20 women with tumors 0.5–0.9 cm, 5 (25 %) initiated trastuzumab. Compliance with trastuzumab was very high among those with HER2-positive breast cancer, as was the completion of the recommended therapy.

KW - Adherence

KW - Adjuvant therapy

KW - Breast cancer

KW - Early discontinuation

KW - Non-initiation

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84939882871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939882871&partnerID=8YFLogxK

U2 - 10.1007/s12282-014-0543-1

DO - 10.1007/s12282-014-0543-1

M3 - Article

C2 - 24902664

AN - SCOPUS:84939882871

VL - 21

SP - 780

EP - 785

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 6

ER -